{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:10:04Z","timestamp":1791155404987,"version":"4.1.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy. In previous in vitro studies, we have shown that the potent immunomodulatory derivative of thalidomide (IMiD) CC-5013 induces apoptosis or growth arrest even in resistant MM cell lines and patient cells, decreases binding of MM cells to bone marrow stromal cells (BMSCs), inhibits the production in the BM milieu of cytokines (interleukin-6 [IL-6], vascular endothelial growth factor [VEGF], tumor necrosis factor-\u03b1 [TNF-\u03b1]) mediating growth and survival of MM cells, blocks angiogenesis, and stimulates host anti-MM natural killer (NK) cell immunity. Moreover, CC-5013 also inhibits tumor growth, decreases angiogenesis, and prolongs host survival in a human plasmacytoma mouse model. In the present study, we carried out a phase 1 CC-5013 dose-escalation (5 mg\/d, 10 mg\/d, 25 mg\/d, and 50 mg\/d) study in 27 patients (median age 57 years; range, 40-71 years) with relapsed and refractory relapsed MM. They received a median of 3 prior regimens (range, 2-6 regimens), including autologous stem cell transplantation and Thal in 15 and 16 patients, respectively. In 24 evaluable patients, no dose-limiting toxicity (DLT) was observed in patients treated at any dose level within the first 28 days; however, grade 3 myelosuppression developed after day 28 in all 13 patients treated with 50 mg\/d CC-5013. In 12 patients, dose reduction to 25 mg\/d was well tolerated and therefore considered the maximal tolerated dose (MTD). Importantly, no significant somnolence, constipation, or neuropathy has been seen in any cohort. Best responses of at least 25% reduction in paraprotein occurred in 17 (71%) of 24 patients (90% confidence interval [CI], 52%-85%), including 11 (46%) patients who had received prior Thal. Stable disease (less than 25% reduction in paraprotein) was observed in an additional 2 (8%) patients. Therefore, 17 (71%) of 24 patients (90% CI, 52%-85%) demonstrated benefit from treatment. Our study therefore provides the basis for the evaluation of CC-5013, either alone or in combination, to treat patients with MM at earlier stages of disease.<\/jats:p>","DOI":"10.1182\/blood-2002-03-0996","type":"journal-article","created":{"date-parts":[[2002,10,16]],"date-time":"2002-10-16T23:03:08Z","timestamp":1034809388000},"page":"3063-3067","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":662,"title":["Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma"],"prefix":"10.1182","volume":"100","author":[{"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Schlossman","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edie","family":"Weller","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teru","family":"Hideshima","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Mitsiades","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Davies","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence P.","family":"Catley","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Doss","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Kelly","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McKenney","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Mechlowicz","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Freeman","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reggie","family":"Deocampo","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Rich","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan J.","family":"Ryoo","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharminder","family":"Chauhan","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathe","family":"Balinski","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Zeldis","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111616334279300_B1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","article-title":"Cancer Statistics, 2001.","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J Clin."},{"key":"2019111616334279300_B2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Anti-tumor activity of thalidomide in refractory multiple myeloma.","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med."},{"key":"2019111616334279300_B3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-\u03ba B.","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood."},{"key":"2019111616334279300_B4","first-page":"1379","article-title":"The 86 kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells.","volume":"101","author":"Teoh","year":"1997","journal-title":"J Clin Invest."},{"key":"2019111616334279300_B5","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.4049\/jimmunol.165.11.6347","article-title":"Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage.","volume":"165","author":"Tai","year":"2000","journal-title":"J Immunol."},{"key":"2019111616334279300_B6","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4049\/jimmunol.159.5.2212","article-title":"Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade.","volume":"159","author":"Ogata","year":"1997","journal-title":"J Immunol."},{"key":"2019111616334279300_B7","doi-asserted-by":"crossref","first-page":"27845","DOI":"10.1074\/jbc.M003428200","article-title":"SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.","volume":"275","author":"Chauhan","year":"2000","journal-title":"J Biol Chem."},{"key":"2019111616334279300_B8","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","article-title":"Biologic sequelae of interleukin-6 induced PI3-K\/AKT signaling in multiple myeloma.","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene."},{"key":"2019111616334279300_B9","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","article-title":"The role of tumor necrosis factor \u03b1 in the pathophysiology of human multiple myeloma: therapeutic applications.","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene."},{"key":"2019111616334279300_B10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood.V98.2.428","article-title":"Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.","volume":"98","author":"Podar","year":"2001","journal-title":"Blood."},{"key":"2019111616334279300_B11","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1074\/jbc.M109068200","article-title":"Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with \u03b2 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC \u03b1 activation.","volume":"277","author":"Podar","year":"2002","journal-title":"J Biol Chem."},{"key":"2019111616334279300_B12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V90.2.754","article-title":"The development of a model for the homing of multiple myeloma cells to human bone marrow.","volume":"90","author":"Urashima","year":"1997","journal-title":"Blood."},{"key":"2019111616334279300_B13","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood."},{"key":"2019111616334279300_B14","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia."},{"key":"2019111616334279300_B15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.","volume":"98","author":"Davies","year":"2001","journal-title":"Blood."},{"key":"2019111616334279300_B16"},{"key":"2019111616334279300_B17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b1.","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol."},{"key":"2019111616334279300_B18","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","article-title":"Amino-substituted thaldidomide analogs: potent inhibitors of TNF-\u03b1 production.","volume":"9","author":"Muller","year":"1999","journal-title":"Bioorg Med Chem Lett."},{"key":"2019111616334279300_B19","first-page":"167a","article-title":"Thalidomide with dexamethasone for resistant multiple myeloma [abstract].","volume":"96","author":"Weber","year":"2000","journal-title":"Blood."},{"key":"2019111616334279300_B20","first-page":"849a","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed multiple myeloma [abstract].","volume":"98","author":"Rajkumar","year":"2001","journal-title":"Blood."},{"key":"2019111616334279300_B21","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/9\/3063\/1257094\/h82102003063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/9\/3063\/1257094\/h82102003063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T19:38:09Z","timestamp":1682365089000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/9\/3063\/16354\/Immunomodulatory-drug-CC5013-overcomes-drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,1]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,11,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-03-0996","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,11,1]]}}}